Stocktoria
ENvue Medical, Inc. FEED
ENvue Medical, Inc. (FEED) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.6M at a -712.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.015 |
| Retained earnings / assets | -2.2 |
| EBIT / assets | -0.557 |
| Equity / liabilities | 4.392 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FEED | ENvue Medical, Inc. | 2/9 | -6.2 | — | — |
| CLGN | CollPlant Biotechnologies Ltd | 3/9 | — | — | — |
| NTRB | NutriBand Inc. | 3/9 | -15.84 | — | — |
| AVR | Anteris Technologies Global Corp. | 2/9 | — | — | — |
| SPAI | Safe Pro Group Inc. | 4/9 | 9.05 | — | — |
| COCH | Envoy Medical, Inc. | 2/9 | — | — | — |
| CUPR | Cuprina Holdings (Cayman) LTD | 4/9 | -2.57 | — | — |
About ENvue Medical, Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.
FAQ
Is FEED financially healthy?
ENvue Medical, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does FEED pay a dividend?
No, ENvue Medical, Inc. does not currently pay a dividend.
How profitable is FEED?
In FY2025, ENvue Medical, Inc. had a net margin of -712.3% and a return on equity of -54.3%.
Is FEED a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ENvue Medical, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.